kinetic securities issue lt spec buy on prr, page-4

i particularly like this part of the report.cvac is in the prime eye for a takeover at any time.if no takeover or cvac buy out further down states that the approval process is quicker since the obama govt getting into office.

Insight - US FDA approval of drugs has declined from 53 in 1996 to 18 in 2007 leaving a
glut of blockbuster drugs coming off patents in the following years. Major pharmaceutical
companies are in desperate need of new multi-billion dollar block buster drugs. This means,
Prima Biomed could become a takeover target.
Of recent the Obama administration has established a new FDA commissioner, Margaret
Hamburg and a new associate commissioner Joshua Sharfstein along with an increased
budget for the FDA. This change of board is positive for Prima as it allows a faster and more
proactive drug approval process.